NASDAQ
7.04USD
-0.06 (-0.85%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
28.5M
P/E
—
EPS
—
Beta
1.04
52W range
6.32-12.6
Day range
7.03–7.15
Open
7.03
Prev close
7.10
Volume
3.2K
Avg volume
15.8K
Dividend
0.00
IPO
2014-11-14
https://seekingalpha.com/article/4936575-kyntra-bio-inc-kynb-q2-2026-earnings-call-transcript · 8/14/2026+0.00
https://www.globenewswire.com/news-release/2026/03/16/3256693/33525/en/Kyntra-Bio-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Business-Update.html · 3/16/2026+0.60
https://www.zacks.com/stock/news/2880911/kyntra-bio-kynb-expected-to-beat-earnings-estimates-what-to-know-ahead-of-q4-release?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_9-2880911 · 3/9/2026-0.60
Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
